Get to know our clinical trials
Clinical trial to evaluate the efficacy on renal function and safety of RMC-035 in participants at elevated risk of renal injury after open heart surgery.
THE MAIN PURPOSE OF THIS RESEARCH STUDY IS TO EVALUATE WHETHER THE STUDY DRUG (RMC-035) PREVENTS KIDNEY DAMAGE AFTER CARDIAC SURGERY IN PARTICIPANTS AT HIGH RISK OF KIDNEY INJURY. ANOTHER OBJECTIVE IS TO LEARN MORE ABOUT THE SAFETY OF RMC-035.
Technical Summary
- PHASE 2B, DOSE-FINDING, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, PHASE 2B CLINICAL STUDY TO EVALUATE THE EFFICACY ON RENAL FUNCTION AND SAFETY OF RMC-035 IN PARTICIPANTS AT ELEVATED RISK OF RENAL INJURY FOLLOWING OPEN CARDIAC SURGERY.
- Code EudraCT: 2024-510658-28
- Protocol number: 24-ROS-07
- Promoter: Guard Therapeutics International AB
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.